SLC2A4 and Insulin resistance: Similarly, SPRC treatment protected diabetic mice from cardiac insulin resistance by activating the AKT/GLUT4 signaling, with no obvious improvement on systemic insulin resistance, which were consistent with the improvement of H2S levels in myocardium but not in plasma.